Genedata AG, have licensed their Genedata Expressionist® software solution to Signature Diagnostics AG. The diagnostics company will use Genedata's software to help them identify unique gene expression profiles found in colorectal cancer (CRC) patients.
"We needed a scalable, regulatory-compliant solution to accommodate our high-throughput diagnostic clinical discovery efforts", says Professor André Rosenthal, CEO, Signature Diagnostics AG.
The software will be used to process and analyze Affymetrix GeneChip data from thousands of CRC patients receiving treatment at dozens of specialized oncology clinics. Using powerful proprietary algorithms, the goal is to identify unique gene expression signatures that predict the risk of recurrence and response to therapy of individual patients.
"Genedata offers the only industrial-scale solution to automate the entire workflow from sample management to statistical analysis and biological interpretation."
"Signature Diagnostics brings tremendous expertise in molecular diagnostics to the challenge of cancer biomarker discovery", says Dr Othmar Pfannes, CTO of Genedata AG. Genedata Expressionist® facilitates tight integration between data, analysis and biomedical knowledge.
Companies scaling up their expression analysis operations quickly encounter the need for automation and standardization. "This is where a platform like Expressionist comes into its own."